Synopsis
Synopsis
0
VMF
0
Australia
0
South Africa
Annual Reports
NA
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 5-chloro-4-(2-imidazolin-2-yl-amino)-2,1,3-benzothiadiazole
2. Ds 103-282
3. Sirdalud
4. Tizanidine
5. Tizanidine Monohydrochloride
6. Zanaflex
1. Tizanidine Hcl
2. 64461-82-1
3. Zanaflex
4. Tizanidine (hydrochloride)
5. 5-chloro-n-(4,5-dihydro-1h-imidazol-2-yl)-2,1,3-benzothiadiazol-4-amine Hydrochloride
6. Ds 103-282
7. An021
8. 5-chloro-n-(4,5-dihydro-1h-imidazol-2-yl)benzo[c][1,2,5]thiadiazol-4-amine Hydrochloride
9. B53e3nmy5c
10. Tizanidine (as Hydrochloride)
11. 5-chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiadiazole Monohydrochloride
12. 5-chloro-n-(4,5-dihydro-1h-imidazol-2-yl)-2,1,3-benzothiadiazol-4-amine;hydrochloride
13. Ds-103-282
14. 5-chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiadiazole Hydrochloride
15. An-021
16. 64461-82-1 (hcl)
17. 2,1,3-benzothiadiazol-4-amine, 5-chloro-n-(4,5-dihydro-1h-imidazol-2-yl)-, Monohydrochloride
18. 5-chloro-n-(4,5-dihydro-1h-imidazol-2-yl)-2,1,3-benzothiadiazole-4-amine Hydrochloride
19. Smr000499584
20. Unii-b53e3nmy5c
21. Sr-01000765392
22. Tizanidine * Hcl
23. Zanaflex (tn)
24. Mfcd00798231
25. Tizanidine Hydrochloride [usan:usp:jan]
26. 5-iodoisoquinolin-8-ol
27. Schembl41199
28. Mls001076686
29. Mls001306412
30. Mls001333593
31. Chebi:9609
32. Tizanidine Hydrochloride- Bio-x
33. Chembl1200329
34. Dtxsid9046990
35. Ds-103282 Ch
36. Hy-b0194a
37. An-021a
38. Nvd-422
39. Amy18121
40. Bcp28540
41. Tox21_501114
42. S1437
43. Tizanidine Hydrochloride [mi]
44. Tizanidine Hydrochloride (jp17/usp)
45. Tizanidine Hydrochloride [jan]
46. Akos005267234
47. Brn0618691
48. Ccg-220602
49. Ccg-222418
50. Ks-1120
51. Lp01114
52. Nc00654
53. Tizanidine Hydrochloride [usan]
54. Tizanidine Hydrochloride [mart.]
55. Tizanidine Hydrochloride [vandf]
56. Ncgc00261799-01
57. Tizanidine Hydrochloride [who-dd]
58. Ac-22546
59. Bt164478
60. Db-011661
61. Ds-103282
62. Ds103-282
63. Ft-0656022
64. Sw199068-2
65. T2527
66. En300-49853
67. Tizanidine Hydrochloride [orange Book]
68. D00776
69. D70434
70. Tizanidine Hydrochloride [ep Monograph]
71. Tizanidine Hydrochloride [usp Impurity]
72. Tizanidine Hydrochloride [usp Monograph]
73. Tizanidine Hydrochloride, >=98% (hplc), Powder
74. Sr-01000765392-4
75. Q27274381
76. Tizanidine Hydrochloride 100 Microg/ml In Acetonitrile
77. 5-chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiadiazolehydrochloride
78. Tizanidine Hydrochloride, European Pharmacopoeia (ep) Reference Standard
79. (5-chloro-2,1,3-benzothiadiazol-4-yl)-(4,5-dihydro-1h-imidazol-2-yl)azanium;chloride
80. 5-(chloro-n-(4,5-dihydro-1h-imidazol-2-yl)-2,1,3-benzothiadiazol-4-amine Hydrochloride
81. 5-chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiadiazole Monohydrochloride.
82. 5-chloro-4-[(4,5-dihydro-1h-imidazol-2-yl)amino]-2,1,3-benzothiadiazole Hydrochloride
83. 5-chloro-n-(4,5-dihydro-1h-imidazol-2-yl)-2,1,3benzothiadiazole-4-amine Hydrochloride
84. 5-chloro-n-(4,5-dihydro-1h-imidazol-2-yl)benzo[c][1,2,5]thiadiazol-4-aminehydrochloride
85. Tizanidine Hydrochloride, 500 Mug/ml In Methanol, Certified Reference Material
86. Tizanidine Hydrochloride, United States Pharmacopeia (usp) Reference Standard
Molecular Weight | 290.17 g/mol |
---|---|
Molecular Formula | C9H9Cl2N5S |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 2 |
Exact Mass | 288.9955719 g/mol |
Monoisotopic Mass | 288.9955719 g/mol |
Topological Polar Surface Area | 90.4 Ų |
Heavy Atom Count | 17 |
Formal Charge | 0 |
Complexity | 300 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Tizanidine hydrochloride |
PubMed Health | Tizanidine (By mouth) |
Drug Classes | Skeletal Muscle Relaxant, Centrally Acting |
Drug Label | Zanaflex (tizanidine hydrochloride) is a centrally acting 2-adrenergic agonist. Tizanidine HCl (tizanidine) is a white to off-white, fine crystalline powder, which is odorless or with a faint characteristic odor. Tizanidine is slightly soluble in... |
Active Ingredient | Tizanidine hydrochloride |
Dosage Form | Tablet; Capsule |
Route | Oral |
Strength | eq 4mg base; eq 2mg base; eq 6mg base |
Market Status | Prescription |
Company | Corepharma; Mylan Pharms; Teva; Apotex; Sun Pharm Inds; Prosam Labs; Sandoz; Dr Reddys Labs; Mylan; Unichem Labs |
2 of 4 | |
---|---|
Drug Name | Zanaflex |
Drug Label | Zanaflex (tizanidine hydrochloride) is a centrally acting 2-adrenergic agonist. Tizanidine HCl (tizanidine) is a white to off-white, fine crystalline powder, which is odorless or with a faint characteristic odor. Tizanidine is slightly soluble in... |
Active Ingredient | Tizanidine hydrochloride |
Dosage Form | Tablet; Capsule |
Route | Oral |
Strength | eq 4mg base; eq 2mg base; eq 6mg base |
Market Status | Prescription |
Company | Acorda |
3 of 4 | |
---|---|
Drug Name | Tizanidine hydrochloride |
PubMed Health | Tizanidine (By mouth) |
Drug Classes | Skeletal Muscle Relaxant, Centrally Acting |
Drug Label | Zanaflex (tizanidine hydrochloride) is a centrally acting 2-adrenergic agonist. Tizanidine HCl (tizanidine) is a white to off-white, fine crystalline powder, which is odorless or with a faint characteristic odor. Tizanidine is slightly soluble in... |
Active Ingredient | Tizanidine hydrochloride |
Dosage Form | Tablet; Capsule |
Route | Oral |
Strength | eq 4mg base; eq 2mg base; eq 6mg base |
Market Status | Prescription |
Company | Corepharma; Mylan Pharms; Teva; Apotex; Sun Pharm Inds; Prosam Labs; Sandoz; Dr Reddys Labs; Mylan; Unichem Labs |
4 of 4 | |
---|---|
Drug Name | Zanaflex |
Drug Label | Zanaflex (tizanidine hydrochloride) is a centrally acting 2-adrenergic agonist. Tizanidine HCl (tizanidine) is a white to off-white, fine crystalline powder, which is odorless or with a faint characteristic odor. Tizanidine is slightly soluble in... |
Active Ingredient | Tizanidine hydrochloride |
Dosage Form | Tablet; Capsule |
Route | Oral |
Strength | eq 4mg base; eq 2mg base; eq 6mg base |
Market Status | Prescription |
Company | Acorda |
Muscle Relaxants, Central
A heterogeneous group of drugs used to produce muscle relaxation, excepting the neuromuscular blocking agents. They have their primary clinical and therapeutic uses in the treatment of muscle spasm and immobility associated with strains, sprains, and injuries of the back and, to a lesser degree, injuries to the neck. They have been used also for the treatment of a variety of clinical conditions that have in common only the presence of skeletal muscle hyperactivity, for example, the muscle spasms that can occur in MULTIPLE SCLEROSIS. (From Smith and Reynard, Textbook of Pharmacology, 1991, p358) (See all compounds classified as Muscle Relaxants, Central.)
Parasympatholytics
Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)
Analgesics
Compounds capable of relieving pain without the loss of CONSCIOUSNESS. (See all compounds classified as Analgesics.)
Anticonvulsants
Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)
Adrenergic alpha-2 Receptor Agonists
Compounds that bind to and activate ADRENERGIC ALPHA-2 RECEPTORS. (See all compounds classified as Adrenergic alpha-2 Receptor Agonists.)
Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.
GDUFA
DMF Review : Reviewed
Rev. Date : 2015-03-03
Pay. Date : 2014-10-14
DMF Number : 15525
Submission : 2001-07-04
Status : Active
Type : II
Registration Number : 227MF10142
Registrant's Address : Na vlcinci 16/3 Klasterni Hradisko 779 00 Olomouc Czech Republic
Initial Date of Registration : 2015-05-20
Latest Date of Registration :
NDC Package Code : 63278-0489
Start Marketing Date : 2003-01-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Kwangdong Pharmaceutical Co., Ltd.
Registration Date : 2021-06-21
Registration Number : 20210421-209-J-493(1)
Manufacturer Name : Farmak, as
Manufacturer Address : Na vlcinci 16/3, Klasterni Hradisko, 779 00 Olomouc, Czech Republic
Available Reg Filing : ASMF |
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-01-23
Pay. Date : 2013-04-12
DMF Number : 15699
Submission : 2001-11-02
Status : Active
Type : II
Date of Issue : 2022-06-06
Valid Till : 2025-06-25
Written Confirmation Number : WC-0035a
Address of the Firm :
NDC Package Code : 55111-020
Start Marketing Date : 2001-11-02
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Available Reg Filing : ASMF |
Tenatra connects Indian manufacturers with global buyers through active partners in Germany, Switzerland, Belgium, Spain & Turkey.
JPN Pharma offers excellence in API manufacturing through precision, innovation & quality, delivering solutions to the pharma industry
Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.
Registrant Name : Klasia Co., Ltd.
Registration Date : 2021-04-21
Registration Number : 20210421-209-J-493
Manufacturer Name : Farmak, as
Manufacturer Address : Na vlcinci 16/3, Klasterni Hradisko, 779 00 Olomouc, Czech Republic
Available Reg Filing : ASMF |
GDUFA
DMF Review : Reviewed
Rev. Date : 2022-02-09
Pay. Date : 2022-01-27
DMF Number : 33900
Submission : 2019-07-09
Status : Active
Type : II
Certificate Number : R0-CEP 2022-256 - Rev 00
Issue Date : 2023-01-05
Type : Chemical
Substance Number : 2578
Status : Valid
Date of Issue : 2022-10-17
Valid Till : 2025-08-08
Written Confirmation Number : WC-0382
Address of the Firm :
NDC Package Code : 66022-0202
Start Marketing Date : 1996-11-27
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Klasia Co., Ltd.
Registration Date : 2021-10-19
Registration Number : 20211019-209-J-1034
Manufacturer Name : M/s.Symed Labs Ltd (Unit-Ⅰ)
Manufacturer Address : Sy. No. 353, Domadugu Village Gummadidala (Mandal), Sangareddy (Dist.), Telangana State, India.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 15739
Submission : 2001-11-12
Status : Active
Type : II
Date of Issue : 2022-06-30
Valid Till : 2025-07-28
Written Confirmation Number : WC-0063
Address of the Firm :
NDC Package Code : 53747-003
Start Marketing Date : 2001-11-12
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
68
PharmaCompass offers a list of Tizanidine HCl API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Tizanidine HCl manufacturer or Tizanidine HCl supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Tizanidine HCl manufacturer or Tizanidine HCl supplier.
PharmaCompass also assists you with knowing the Tizanidine HCl API Price utilized in the formulation of products. Tizanidine HCl API Price is not always fixed or binding as the Tizanidine HCl Price is obtained through a variety of data sources. The Tizanidine HCl Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Zanaflex manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Zanaflex, including repackagers and relabelers. The FDA regulates Zanaflex manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Zanaflex API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Zanaflex manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Zanaflex supplier is an individual or a company that provides Zanaflex active pharmaceutical ingredient (API) or Zanaflex finished formulations upon request. The Zanaflex suppliers may include Zanaflex API manufacturers, exporters, distributors and traders.
click here to find a list of Zanaflex suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Zanaflex DMF (Drug Master File) is a document detailing the whole manufacturing process of Zanaflex active pharmaceutical ingredient (API) in detail. Different forms of Zanaflex DMFs exist exist since differing nations have different regulations, such as Zanaflex USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Zanaflex DMF submitted to regulatory agencies in the US is known as a USDMF. Zanaflex USDMF includes data on Zanaflex's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Zanaflex USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Zanaflex suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Zanaflex Drug Master File in Japan (Zanaflex JDMF) empowers Zanaflex API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Zanaflex JDMF during the approval evaluation for pharmaceutical products. At the time of Zanaflex JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Zanaflex suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Zanaflex Drug Master File in Korea (Zanaflex KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Zanaflex. The MFDS reviews the Zanaflex KDMF as part of the drug registration process and uses the information provided in the Zanaflex KDMF to evaluate the safety and efficacy of the drug.
After submitting a Zanaflex KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Zanaflex API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Zanaflex suppliers with KDMF on PharmaCompass.
A Zanaflex CEP of the European Pharmacopoeia monograph is often referred to as a Zanaflex Certificate of Suitability (COS). The purpose of a Zanaflex CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Zanaflex EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Zanaflex to their clients by showing that a Zanaflex CEP has been issued for it. The manufacturer submits a Zanaflex CEP (COS) as part of the market authorization procedure, and it takes on the role of a Zanaflex CEP holder for the record. Additionally, the data presented in the Zanaflex CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Zanaflex DMF.
A Zanaflex CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Zanaflex CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Zanaflex suppliers with CEP (COS) on PharmaCompass.
A Zanaflex written confirmation (Zanaflex WC) is an official document issued by a regulatory agency to a Zanaflex manufacturer, verifying that the manufacturing facility of a Zanaflex active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Zanaflex APIs or Zanaflex finished pharmaceutical products to another nation, regulatory agencies frequently require a Zanaflex WC (written confirmation) as part of the regulatory process.
click here to find a list of Zanaflex suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Zanaflex as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Zanaflex API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Zanaflex as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Zanaflex and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Zanaflex NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Zanaflex suppliers with NDC on PharmaCompass.
Zanaflex Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Zanaflex GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Zanaflex GMP manufacturer or Zanaflex GMP API supplier for your needs.
A Zanaflex CoA (Certificate of Analysis) is a formal document that attests to Zanaflex's compliance with Zanaflex specifications and serves as a tool for batch-level quality control.
Zanaflex CoA mostly includes findings from lab analyses of a specific batch. For each Zanaflex CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Zanaflex may be tested according to a variety of international standards, such as European Pharmacopoeia (Zanaflex EP), Zanaflex JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Zanaflex USP).